United States CAR-T Cell Therapy Market to Grow with a CAGR of 9.85% through 2030

Increasing Incidence of Cancer and Aging Population is expected to drive the United States CAR-T Cell Therapy Market growth in the forecast period, 2026-2030

According to TechSci Research report, “United States CAR-T Cell Therapy Market – By Region, Competition, Forecast & Opportunities, 2030F”, the United States CAR-T Cell Therapy Market stood at USD 3.25 Billion in 2024 and is anticipated to grow with a CAGR of 9.85% in the forecast period, 2026-2030.

CAR-T cell therapy is a key segment within the broader immunotherapy market, which has experienced significant technological progress. By harnessing the body's immune system to target and fight cancer, CAR-T therapies offer a more precise approach compared to traditional treatments like chemotherapy. The success of early CAR-T therapies such as Kymriah and Yescarta have validated their therapeutic potential, stimulating further research and development in the field. The regulatory environment in the United States has been highly supportive of CAR-T therapies, with the FDA approving multiple CAR-T cell treatments in recent years. The accelerated approval process for therapies like Kymriah (Novartis) and Yescarta (Gilead) has expedited patient access, driving market expansion. Additionally, initiatives such as Breakthrough Therapy Designation and Orphan Drug Status have further fueled innovation and market growth in this sector.

Originally focused on treating blood cancers, CAR-T therapies are now being explored for solid tumors, significantly broadening the potential patient base. This expansion into solid tumor applications, including breast, lung, and pancreatic cancers, is poised to drive market growth by increasing the addressable patient population. Ongoing clinical trials are focused on evaluating the effectiveness of CAR-T therapies in these new indications. Substantial investments from pharmaceutical companies and venture capital play a pivotal role in advancing CAR-T therapy development. These investments are essential for progressing clinical trials, improving manufacturing processes, and optimizing the safety and efficacy of CAR-T treatments. R&D efforts are also focused on overcoming key challenges such as high treatment costs, off-target effects, and the complexity of CAR-T cell manufacturing.

Pharmaceutical companies are increasingly forming strategic partnerships to leverage expertise in the development of CAR-T therapies. Collaborations between biotech firms, academic institutions, and large pharmaceutical companies are accelerating the development of next-generation CAR-T therapies. These partnerships facilitate resource sharing across R&D, regulatory processes, and distribution channels, which fuel rapid market growth. Advancements in CAR-T cell manufacturing processes are critical to the market's growth. Improvements in automation, genetic engineering, and supply chain management have reduced both the time and costs associated with manufacturing. Additionally, the development of off-the-shelf CAR-T therapies, including allogeneic options, is expected to make treatments more affordable and accessible, further driving their adoption.

Browse over XX market data Figures spread through XX Pages and an in-depth TOC on "United States CAR-T Cell Therapy Market”

The United States CAR-T Cell Therapy Market is segmented into product, disease, end user, regional distribution, and company.

Based on its disease, the lymphoma segment has emerged as the predominant market leader, CAR-T therapies like Yescarta (Gilead) and Kymriah (Novartis) have demonstrated considerable success in treating diffuse large B-cell lymphoma (DLBCL), a subtype of non-Hodgkin lymphoma. These treatments have received FDA approval, establishing CAR-T as a highly effective option for relapsed or refractory lymphoma patients who have not responded to conventional therapies.

Lymphoma accounts for a substantial portion of cancer cases, with a high incidence of relapsed or refractory disease, making CAR-T therapy an attractive treatment option. The approval of CAR-T therapies has increased the demand for these treatments, particularly for patients with aggressive forms of lymphoma. CAR-T therapies have shown promising results in terms of long-term remission and overall survival rates for lymphoma patients, which has contributed to the strong market position of this segment. The ability to achieve durable responses, even in difficult-to-treat cases, has positioned lymphoma as the leading market segment for CAR-T therapies.

Major companies operating in United States CAR-T Cell Therapy Market are:

• Gilead Sciences, Inc (US)
• Novartis United States
• AbbVie Inc.
• Myriad Genetics
• NeoGenomics Laboratories
• Intellia Therapeutics (US)
• Agilent Technologies, Inc. (US)
• Abcam plc.
• Bio-Techne. (ExoDx)
• Sangamo Therapeutics, Inc. (US)

Download Free Sample Report

Customers can also request for 10% free customization on this report

“The United States CAR-T cell therapy market is poised for continued robust growth, driven by technological advancements, expanding clinical indications, and increasing regulatory support. With the successful application of CAR-T therapies in hematologic cancers like lymphoma, leukemia, and multiple myeloma, as well as the ongoing research into solid tumors, the market holds significant promise. Strategic investments in R&D, improvements in manufacturing processes, and evolving reimbursement policies further support the market’s expansion. Despite challenges such as high treatment costs and accessibility, the CAR-T therapy market is set to play a pivotal role in the future of cancer treatment, offering new hope for patients and reshaping the oncology landscape.,” said Mr. Karan Chechi, Research Director of TechSci Research, a research-based management consulting firm.

“United States CAR-T Cell Therapy Market, By Product (Abecma (idecabtagene vicleucel), Breyanzi (lisocabtagene maraleucel), Carvykti (ciltacabtagene autoleucel), Kymriah (tisagenlecleucel), Tecartus (brexucabtagene autoleucel), Yescarta (axicabtagene ciloleucel), Others), By Disease (Leukemia, Lymphoma, Multiple Myeloma, Others), By End User (Hospitals, Cancer Treatment Centers), By Region, Competition, Forecast & Opportunities, 2020-2030F”, has evaluated the future growth potential of United States CAR-T Cell Therapy Market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in United States CAR-T Cell Therapy Market.

Contact

TechSci Research LLC

420 Lexington Avenue, Suite 300,

New York, United States- 10170

Tel: +1-332-258-6602

Email: [email protected]